Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	methionine adenosyltransferase activity	MAT1A MAT2A	3.95e-05	2	126	2	GO:0004478
GeneOntologyMolecularFunction	succinyl-CoA:3-oxo-acid CoA-transferase activity	OXCT2 OXCT1	3.95e-05	2	126	2	GO:0008260
GeneOntologyBiologicalProcess	regulation of cell development	SOX2 NPR2 NOG FN1 DLL4 TBX21 CEACAM7 GATA1 APC AMBRA1 SOX8 ARID1A CR1 ZBTB7A HOXB3 ARID1B TENM4 EIF4G2 RBFOX2 WDR62	1.06e-05	1095	126	20	GO:0060284
GeneOntologyBiologicalProcess	definitive erythrocyte differentiation	GATA1 NCOR1 RBFOX2	1.22e-05	8	126	3	GO:0060318
GeneOntologyBiologicalProcess	definitive hemopoiesis	GATA1 NCOR1 HOXB3 RBFOX2	2.09e-05	27	126	4	GO:0060216
GeneOntologyBiologicalProcess	cell fate commitment	SOX2 DLL4 TBX21 GATA1 SOX17 APC SOX8 TENM4 PTCH2 TNXB	4.39e-05	338	126	10	GO:0045165
GeneOntologyBiologicalProcess	growth	SOX2 CACNA1C NPR2 NOG FN1 CEACAM7 HLA-H SOX17 APC TNS2 SIK3 NCOR1 NLGN3 HSD3B7 TENM4 EIF4G2 PTCH2 MBD5 EN1 MED12	5.86e-05	1235	126	20	GO:0040007
GeneOntologyBiologicalProcess	positive regulation of cell differentiation	SOX2 BOC NOG FN1 CEACAM7 GATA1 SOX17 APC AMBRA1 SOX8 ARID1A CR1 ARID1B TENM4 LPL EIF4G2 PTCH2 TNXB WDR62	6.34e-05	1141	126	19	GO:0045597
GeneOntologyBiologicalProcess	cell fate specification	SOX2 TBX21 SOX17 APC TENM4 PTCH2	1.09e-04	123	126	6	GO:0001708
GeneOntologyBiologicalProcess	cardiac cell fate specification	SOX17 TENM4	1.11e-04	3	126	2	GO:0060912
GeneOntologyBiologicalProcess	ketone body catabolic process	OXCT2 OXCT1	1.11e-04	3	126	2	GO:0046952
GeneOntologyBiologicalProcess	embryonic morphogenesis	SOX2 CACNA1C NOG FN1 DLL4 SOX17 SOX8 ARID1A FREM2 HOXB3 TENM4 HOXD9 EN1 MED12	1.18e-04	713	126	14	GO:0048598
GeneOntologyBiologicalProcess	central nervous system development	SOX2 NOG TFAP2D KIF1A DLL4 MEIS3 SOX8 ARID1A ANKLE2 NCOR1 NLGN3 HOXB3 KCNA3 TENM4 CELSR2 EN1 MED12 RBFOX2 WDR62	1.19e-04	1197	126	19	GO:0007417
GeneOntologyBiologicalProcess	developmental growth	SOX2 CACNA1C NPR2 NOG FN1 HLA-H APC TNS2 SIK3 NCOR1 NLGN3 TENM4 EIF4G2 MBD5 EN1 MED12	1.38e-04	911	126	16	GO:0048589
GeneOntologyBiologicalProcess	anterior/posterior pattern specification	NOG SOX17 APC HOXB3 CELSR2 HOXD9 EN1 MED12	1.41e-04	247	126	8	GO:0009952
GeneOntologyBiologicalProcess	appendage morphogenesis	CACNA1C NPR2 NOG SIK3 FREM2 HOXD9 EN1	1.43e-04	185	126	7	GO:0035107
GeneOntologyBiologicalProcess	limb morphogenesis	CACNA1C NPR2 NOG SIK3 FREM2 HOXD9 EN1	1.43e-04	185	126	7	GO:0035108
GeneOntologyBiologicalProcess	endoderm development	SOX2 NOG FN1 SOX17 MED12	2.05e-04	88	126	5	GO:0007492
GeneOntologyBiologicalProcess	regulation of definitive erythrocyte differentiation	GATA1 RBFOX2	2.20e-04	4	126	2	GO:0010724
GeneOntologyBiologicalProcess	S-adenosylmethionine biosynthetic process	MAT1A MAT2A	2.20e-04	4	126	2	GO:0006556
GeneOntologyBiologicalProcess	endoderm formation	SOX2 NOG FN1 SOX17	2.27e-04	49	126	4	GO:0001706
GeneOntologyCellularComponent	methionine adenosyltransferase complex	MAT1A MAT2A	1.08e-04	3	126	2	GO:0048269
Domain	3-oxoacid_CoA-transf_A	OXCT2 OXCT1	4.44e-05	2	125	2	IPR012792
Domain	3-oxoacid_CoA-transf_B	OXCT2 OXCT1	4.44e-05	2	125	2	IPR012791
Domain	S-AdoMet_synt_N	MAT1A MAT2A	4.44e-05	2	125	2	PF00438
Domain	CoA_transf_AS	OXCT2 OXCT1	4.44e-05	2	125	2	IPR004164
Domain	CoA_trans_fam_I	OXCT2 OXCT1	4.44e-05	2	125	2	IPR004165
Domain	CoA_transf_BS	OXCT2 OXCT1	4.44e-05	2	125	2	IPR004163
Domain	3-oxoacid_CoA-transferase	OXCT2 OXCT1	4.44e-05	2	125	2	IPR014388
Domain	BAF250/Osa	ARID1A ARID1B	4.44e-05	2	125	2	IPR021906
Domain	S-AdoMet_synthetase	MAT1A MAT2A	4.44e-05	2	125	2	IPR002133
Domain	Lipo_Lipase	LIPG LPL	4.44e-05	2	125	2	IPR002330
Domain	BAF250_C	ARID1A ARID1B	4.44e-05	2	125	2	IPR033388
Domain	CoA_trans	OXCT2 OXCT1	4.44e-05	2	125	2	SM00882
Domain	S-AdoMet_synt_M	MAT1A MAT2A	4.44e-05	2	125	2	PF02772
Domain	S-AdoMet_synt_C	MAT1A MAT2A	4.44e-05	2	125	2	PF02773
Domain	ADOMET_SYNTHASE_CS	MAT1A MAT2A	4.44e-05	2	125	2	IPR022631
Domain	S-AdoMet_synt_C	MAT1A MAT2A	4.44e-05	2	125	2	IPR022630
Domain	S-AdoMet_synthetase_sfam	MAT1A MAT2A	4.44e-05	2	125	2	IPR022636
Domain	S-AdoMet_synt_central	MAT1A MAT2A	4.44e-05	2	125	2	IPR022629
Domain	S-AdoMet_synt_N	MAT1A MAT2A	4.44e-05	2	125	2	IPR022628
Domain	CoA_trans	OXCT2 OXCT1	4.44e-05	2	125	2	PF01144
Domain	BAF250_C	ARID1A ARID1B	4.44e-05	2	125	2	PF12031
Domain	ADOMET_SYNTHASE_1	MAT1A MAT2A	4.44e-05	2	125	2	PS00376
Domain	ADOMET_SYNTHASE_2	MAT1A MAT2A	4.44e-05	2	125	2	PS00377
Domain	COA_TRANSF_2	OXCT2 OXCT1	4.44e-05	2	125	2	PS01274
Domain	COA_TRANSF_1	OXCT2 OXCT1	4.44e-05	2	125	2	PS01273
Domain	EGF_extracell	DLL4 SVEP1 TENM4 LTBP2 TNXB	5.04e-05	60	125	5	IPR013111
Domain	EGF_2	DLL4 SVEP1 TENM4 LTBP2 TNXB	5.04e-05	60	125	5	PF07974
Domain	3Beta_HSD	SDR42E1 HSD3B7	6.55e-04	6	125	2	PF01073
Domain	3Beta_OHSteriod_DH/Estase	SDR42E1 HSD3B7	6.55e-04	6	125	2	IPR002225
Domain	Calx_beta	FREM1 FREM2	1.55e-03	9	125	2	IPR003644
Domain	Calx-beta	FREM1 FREM2	1.55e-03	9	125	2	PF03160
Domain	EGF	DLL4 SVEP1 CELSR2 LTBP2 TNXB	1.59e-03	126	125	5	PF00008
Domain	EGF_1	FN1 DLL4 SVEP1 TENM4 CELSR2 LTBP2 TNXB	1.66e-03	255	125	7	PS00022
Domain	EGF-like_CS	FN1 DLL4 SVEP1 TENM4 CELSR2 LTBP2 TNXB	1.89e-03	261	125	7	IPR013032
Domain	Lipase/vitellogenin	LIPG LPL	1.93e-03	10	125	2	IPR013818
Domain	TAG_lipase	LIPG LPL	1.93e-03	10	125	2	IPR000734
Domain	Lipase	LIPG LPL	1.93e-03	10	125	2	PF00151
Domain	Lipase_N	LIPG LPL	1.93e-03	10	125	2	IPR033906
Domain	Lipase_LIPH	LIPG LPL	1.93e-03	10	125	2	IPR016272
Domain	ARM-like	APC ARMC9 ARID1A ARID1B RRP12 MN1 MED12	2.29e-03	270	125	7	IPR011989
Domain	-	RHOXF2 MEIS3 NCOR1 HOXB3 RHOXF2B HOXD9 EN1	2.97e-03	283	125	7	1.10.10.60
Domain	-	FN1 IGF2R	3.30e-03	13	125	2	2.10.10.10
Domain	-	APC ARMC9 ARID1A ARID1B RRP12 MED12	3.83e-03	222	125	6	1.25.10.10
Domain	FN_type2_col-bd	FN1 IGF2R	3.84e-03	14	125	2	IPR000562
Domain	FN2_2	FN1 IGF2R	3.84e-03	14	125	2	PS51092
Domain	FN2_1	FN1 IGF2R	3.84e-03	14	125	2	PS00023
Domain	fn2	FN1 IGF2R	3.84e-03	14	125	2	PF00040
Domain	FN2	FN1 IGF2R	3.84e-03	14	125	2	SM00059
Domain	Growth_fac_rcpt_	DLL4 SVEP1 CELSR2 LTBP2 TNXB	4.00e-03	156	125	5	IPR009030
Domain	-	ARID1A ARID1B	4.41e-03	15	125	2	1.10.150.60
Domain	BRIGHT	ARID1A ARID1B	4.41e-03	15	125	2	SM00501
Domain	ARID_dom	ARID1A ARID1B	4.41e-03	15	125	2	IPR001606
Domain	ARID	ARID1A ARID1B	4.41e-03	15	125	2	PS51011
Domain	Pept_M10A_Zn_BS	MMP3 MMP11	4.41e-03	15	125	2	IPR021158
Domain	ARID	ARID1A ARID1B	4.41e-03	15	125	2	PF01388
Domain	ASX_HYDROXYL	DLL4 SVEP1 CELSR2 LTBP2	4.57e-03	100	125	4	PS00010
Domain	Homeobox	RHOXF2 MEIS3 HOXB3 RHOXF2B HOXD9 EN1	4.94e-03	234	125	6	PF00046
Domain	EGF	DLL4 SVEP1 TENM4 CELSR2 LTBP2 TNXB	5.04e-03	235	125	6	SM00181
Domain	EGF_3	DLL4 SVEP1 TENM4 CELSR2 LTBP2 TNXB	5.04e-03	235	125	6	PS50026
Domain	Sushi	CR1 SVEP1 GABBR1	5.09e-03	52	125	3	PF00084
Domain	HOMEOBOX_1	RHOXF2 MEIS3 HOXB3 RHOXF2B HOXD9 EN1	5.14e-03	236	125	6	PS00027
Domain	HOX	RHOXF2 MEIS3 HOXB3 RHOXF2B HOXD9 EN1	5.25e-03	237	125	6	SM00389
Domain	HMG_box	SOX2 SOX17 SOX8	5.37e-03	53	125	3	PF00505
Domain	HOMEOBOX_2	RHOXF2 MEIS3 HOXB3 RHOXF2B HOXD9 EN1	5.46e-03	239	125	6	PS50071
Domain	Homeobox_dom	RHOXF2 MEIS3 HOXB3 RHOXF2B HOXD9 EN1	5.46e-03	239	125	6	IPR001356
Domain	EGF-type_Asp/Asn_hydroxyl_site	DLL4 SVEP1 CELSR2 LTBP2	5.62e-03	106	125	4	IPR000152
Domain	Hemopexin_CS	MMP3 MMP11	5.66e-03	17	125	2	IPR018486
Domain	HMG_BOX_2	SOX2 SOX17 SOX8	5.66e-03	54	125	3	PS50118
Domain	HMG	SOX2 SOX17 SOX8	5.66e-03	54	125	3	SM00398
Domain	CCP	CR1 SVEP1 GABBR1	5.66e-03	54	125	3	SM00032
Domain	-	SOX2 SOX17 SOX8	5.96e-03	55	125	3	1.10.30.10
Domain	SUSHI	CR1 SVEP1 GABBR1	6.27e-03	56	125	3	PS50923
Domain	LH2	LIPG LPL	6.34e-03	18	125	2	SM00308
Domain	Pept_M10A_stromelysin-type	MMP3 MMP11	6.34e-03	18	125	2	IPR016293
Domain	Sushi_SCR_CCP_dom	CR1 SVEP1 GABBR1	6.58e-03	57	125	3	IPR000436
Domain	EGF-like_dom	DLL4 SVEP1 TENM4 CELSR2 LTBP2 TNXB	6.64e-03	249	125	6	IPR000742
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MAN2B1 BCAS3 SIPA1L3 AMBRA1 RHOT2 ARID1A NCOR1 IGF2R SHANK2 EIF4ENIF1 CELSR2 ZMIZ2 RRP12 USP7 MBD5 DNMBP CPVL MED12 CYB5R2	2.17e-08	1105	127	19	35748872
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	SIPA1L3 APC SIK3 ANKLE2 NCOR1 IGF2R EIF4ENIF1 SVIL EIF4G2 DNMBP RBFOX2 WDR62 FAM110B BRWD1	3.07e-06	853	127	14	28718761
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	MAN2B1 UGGT1 DCBLD1 CEMIP2 IGF2R TXNDC15 CELSR2 LOXL1 MANEAL LPL RRP12 SVIL LTBP2 CPVL ADGRA3 WDR62	8.29e-06	1201	127	16	35696571
Pubmed	Construction of a multi-functional cDNA library specific for mouse pancreatic islets and its application to microarray.	CACNA1C HLA-H VTA1 MEIS3 IGF2R SVIL MTCL1 DNMBP ATG16L2	9.52e-06	371	127	9	15747579
Pubmed	Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.	ARID1A NCOR1 ARID1B CPVL RBFOX2	1.02e-05	78	127	5	28611094
Pubmed	Lipoprotein lipase and endothelial lipase in human testis and in germ cell neoplasms.	LIPG LPL	1.32e-05	2	127	2	19780863
Pubmed	Cloning and characterization of Ehox, a novel homeobox gene essential for embryonic stem cell differentiation.	RHOXF2 RHOXF2B	1.32e-05	2	127	2	12087094
Pubmed	LRF inhibits p53 expression in colon cancer cells via modulating DAP5 activity.	ZBTB7A EIF4G2	1.32e-05	2	127	2	28849590
Pubmed	Differential expression of succinyl CoA transferase (SCOT) genes in somatic and germline cells of the mouse testis.	OXCT2 OXCT1	1.32e-05	2	127	2	12534938
Pubmed	Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression.	MAT1A MAT2A	1.32e-05	2	127	2	22318685
Pubmed	SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention.	SOX2 FN1	1.32e-05	2	127	2	23895273
Pubmed	SOX2 contributes to melanoma cell invasion.	SOX2 MMP3	1.32e-05	2	127	2	22184093
Pubmed	Elucidation of the low-expressing erythroid CR1 phenotype by bioinformatic mining of the GATA1-driven blood-group regulome.	GATA1 CR1	1.32e-05	2	127	2	37591894
Pubmed	Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis.	ARID1A ARID1B	1.32e-05	2	127	2	37611161
Pubmed	Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.	ARID1A ARID1B	1.32e-05	2	127	2	32791957
Pubmed	A novel mechanism of the M1-M2 methionine adenosyltransferase switch-mediated hepatocellular carcinoma metastasis.	MAT1A MAT2A	1.32e-05	2	127	2	29749642
Pubmed	Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion.	LIPG LPL	1.32e-05	2	127	2	17093291
Pubmed	Dysregulation of placental endothelial lipase and lipoprotein lipase in intrauterine growth-restricted pregnancies.	LIPG LPL	1.32e-05	2	127	2	17356047
Pubmed	Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.	ARID1A ARID1B	1.32e-05	2	127	2	28967863
Pubmed	Deubiquitylase USP7 regulates human terminal erythroid differentiation by stabilizing GATA1.	GATA1 USP7	1.32e-05	2	127	2	30872372
Pubmed	Differential expression of SOX2 and SOX17 in testicular germ cell tumors.	SOX17 SOX8	1.32e-05	2	127	2	19369635
Pubmed	Alterations of Methionine Metabolism as Potential Targets for the Prevention and Therapy of Hepatocellular Carcinoma.	MAT1A MAT2A	1.32e-05	2	127	2	31234428
Pubmed	Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma.	MAT1A MAT2A	1.32e-05	2	127	2	29448301
Pubmed	Identification of a tandem duplicated array in the Rhox alpha locus on mouse chromosome X.	RHOXF2 RHOXF2B	1.32e-05	2	127	2	16465597
Pubmed	Cloning and characterization of the 5'-flanking region of the Ehox gene.	RHOXF2 RHOXF2B	1.32e-05	2	127	2	16414020
Pubmed	Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes.	ARID1A ARID1B	1.32e-05	2	127	2	34386776
Pubmed	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.	ARID1A ARID1B	1.32e-05	2	127	2	23202128
Pubmed	Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate.	SOX2 SOX17	1.32e-05	2	127	2	31583686
Pubmed	ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics.	ARID1A ARID1B	1.32e-05	2	127	2	33890484
Pubmed	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue.	LIPG LPL	1.32e-05	2	127	2	15630456
Pubmed	ARID1A loss in adult hepatocytes activates β-catenin-mediated erythropoietin transcription.	APC ARID1A	1.32e-05	2	127	2	33084574
Pubmed	ARID1B is a specific vulnerability in ARID1A-mutant cancers.	ARID1A ARID1B	1.32e-05	2	127	2	24562383
Pubmed	A homozygous mutation p.Arg2167Trp in FREM2 causes isolated cryptophthalmos.	FREM1 FREM2	1.32e-05	2	127	2	29688405
Pubmed	S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells.	MAT1A MAT2A	1.32e-05	2	127	2	27076759
Pubmed	USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development.	APC USP7	1.32e-05	2	127	2	36669491
Pubmed	ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.	ARID1A ARID1B	1.32e-05	2	127	2	29890703
Pubmed	SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.	ARID1A ARID1B	1.32e-05	2	127	2	24788099
Pubmed	Rhox homeobox gene cluster: recent duplication of three family members.	RHOXF2 RHOXF2B	1.32e-05	2	127	2	16496311
Pubmed	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.	ARID1A ARID1B	1.32e-05	2	127	2	33052929
Pubmed	Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates.	TBX21 ARID1A	1.32e-05	2	127	2	37315534
Pubmed	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.	ARID1A ARID1B	1.32e-05	2	127	2	27562491
Pubmed	Delta-like 4/Notch signaling promotes Apc Min/+ tumor initiation through angiogenic and non-angiogenic related mechanisms.	DLL4 APC	1.32e-05	2	127	2	28086833
Pubmed	Deciphering the Sox-Oct partner code by quantitative cooperativity measurements.	SOX2 SOX17 SOX8	1.32e-05	13	127	3	22344693
Pubmed	Numerous members of the Sox family of HMG box-containing genes are expressed in developing mouse teeth.	SOX2 SOX17 SOX8	1.68e-05	14	127	3	8921394
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	BCAS3 PPP1R3E SIPA1L3 APC SIK3 STARD9 SH3D19 SVIL CCSER2 MTCL1 DNMBP WDR62 FAM110B	1.70e-05	861	127	13	36931259
Pubmed	Sprouty1 haploinsufficiency prevents renal agenesis in a model of Fraser syndrome.	FN1 FREM1 FREM2	2.10e-05	15	127	3	23064016
Pubmed	The versican-hyaluronan complex provides an essential extracellular matrix niche for Flk1+ hematoendothelial progenitors.	FN1 GATA1 CEMIP2	2.57e-05	16	127	3	33454424
Pubmed	Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease.	CELSR2 LIPG LPL	2.57e-05	16	127	3	20691829
Pubmed	Amerindian-specific regions under positive selection harbour new lipid variants in Latinos.	SIK3 CELSR2 LPL	2.57e-05	16	127	3	24886709
Pubmed	Spatio-temporal expression of Sox genes in murine palatogenesis.	SOX2 SOX17 SOX8	3.11e-05	17	127	3	27241892
Pubmed	Expression of Sox genes in tooth development.	SOX2 SOX17 SOX8	3.73e-05	18	127	3	26864488
Pubmed	Leveraging electronic health records to study pleiotropic effects on bipolar disorder and medical comorbidities.	CACNA1C SVEP1	3.96e-05	3	127	2	27529678
Pubmed	Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle.	ARID1A ARID1B	3.96e-05	3	127	2	21647563
Pubmed	Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits.	MAT1A MAT2A	3.96e-05	3	127	2	23425511
Pubmed	SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.	SOX2 FN1	3.96e-05	3	127	2	31922212
Pubmed	The structure of Sox17 bound to DNA reveals a conserved bending topology but selective protein interaction platforms.	SOX2 SOX17	3.96e-05	3	127	2	19328208
Pubmed	Multiple species of mammalian S-adenosylmethionine synthetase. Partial purification and characterization.	MAT1A MAT2A	3.96e-05	3	127	2	7213623
Pubmed	The rhox homeobox gene family shows sexually dimorphic and dynamic expression during mouse embryonic gonad development.	RHOXF2 RHOXF2B	3.96e-05	3	127	2	18562707
Pubmed	LFA-1 knockout inhibited the tumor growth and is correlated with treg cells.	APC ITGAL	3.96e-05	3	127	2	37723552
Pubmed	Comparative analyses of lipoprotein lipase, hepatic lipase, and endothelial lipase, and their binding properties with known inhibitors.	LIPG LPL	3.96e-05	3	127	2	23991054
Pubmed	The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer.	SOX2 SOX17	3.96e-05	3	127	2	25868860
Pubmed	Structure and function study of the complex that synthesizes S-adenosylmethionine.	MAT1A MAT2A	3.96e-05	3	127	2	25075345
Pubmed	Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression.	MMP3 MMP11	3.96e-05	3	127	2	8175886
Pubmed	Higher order lipase gene association with plasma triglycerides.	LIPG LPL	3.96e-05	3	127	2	15961789
Pubmed	Role of SN1 lipases on plasma lipids in metabolic syndrome and obesity.	LIPG LPL	3.96e-05	3	127	2	24458708
Pubmed	ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.	ARID1A ARID1B	3.96e-05	3	127	2	34512623
Pubmed	Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix.	ARID1A ARID1B	3.96e-05	3	127	2	33432679
Pubmed	Expression of tenascin in developing and adult mouse lymphoid organs.	FN1 TNXB	3.96e-05	3	127	2	7687262
Pubmed	Characterization of the lipolytic activity of endothelial lipase.	LIPG LPL	3.96e-05	3	127	2	12032167
Pubmed	TNPO1-mediated nuclear import of ARID1B promotes tumor growth in ARID1A-deficient gynecologic cancer.	ARID1A ARID1B	3.96e-05	3	127	2	34044070
Pubmed	Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.	ARID1A ARID1B	3.96e-05	3	127	2	26716708
Pubmed	Dll4 Blockade Promotes Angiogenesis in Nonhealing Wounds of Sox7-Deficient Mice.	DLL4 SOX17	3.96e-05	3	127	2	33095124
Pubmed	Supervillin-mediated suppression of p53 protein enhances cell survival.	SVIL USP7	3.96e-05	3	127	2	23382381
Pubmed	Cloning and characterization of a human orthologue of testis-specific succinyl CoA: 3-oxo acid CoA transferase (Scot-t) cDNA.	OXCT2 OXCT1	3.96e-05	3	127	2	11756565
Pubmed	Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification.	SOX2 SOX17	3.96e-05	3	127	2	27132888
Pubmed	The RHOX5 homeodomain protein mediates transcriptional repression of the netrin-1 receptor gene Unc5c.	RHOXF2 RHOXF2B	3.96e-05	3	127	2	18077458
Pubmed	Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.	ARID1A ARID1B	3.96e-05	3	127	2	22426308
Pubmed	Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.	ARID1A ARID1B	3.96e-05	3	127	2	24382590
Pubmed	Methionine adenosyltransferase 2A regulates mouse zygotic genome activation and morula to blastocyst transition†.	MAT1A MAT2A	3.96e-05	3	127	2	30265288
Pubmed	Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations.	SOX2 WDR62	3.96e-05	3	127	2	20729831
Pubmed	Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma.	DTX3 DTX3L	3.96e-05	3	127	2	31854042
Pubmed	Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.	SIPA1L3 APC ARID1A ARID1B EIF4ENIF1 CCSER2 MTCL1 CPVL WDR62	4.04e-05	446	127	9	24255178
Pubmed	Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes.	SOX2 SOX8 ARID1A NCOR1	4.32e-05	53	127	4	21532573
Pubmed	Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder.	CACNA1C SVEP1 TENM4	4.41e-05	19	127	3	18711365
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	SIPA1L3 APC SIK3 NCOR1 NLGN3 FRY IGF2R KCNA3 SHANK2 CELSR2 SH3D19 SVIL MTCL1	5.39e-05	963	127	13	28671696
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	APC ARID1A ANKLE2 EIF4ENIF1 SVIL CCSER2 DNMBP	5.39e-05	263	127	7	34702444
Pubmed	Expression of Sox transcription factors in the developing mouse pancreas.	SOX2 SOX17 SOX8	6.03e-05	21	127	3	12815626
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	SOX2 KIF1A RHOXF2 DTX3 TBX21 GATA1 MEIS3 ARID1A RHOXF2B ZMIZ2 ZBTB3	6.13e-05	709	127	11	22988430
Pubmed	Functional proteomics mapping of a human signaling pathway.	MAN2B1 FN1 RHOT2 ANKLE2 SVEP1 NCOR1 ARID1B EIF4G2 MMP11 ZBTB3	6.57e-05	591	127	10	15231748
Pubmed	Human transcription factor protein interaction networks.	SOX2 GATA1 SOX17 RHOT2 RAD54L2 ARID1A NCOR1 ZBTB7A ARID1B EIF4ENIF1 ZMIZ2 RRP12 SVIL USP7 EN1 CPVL	6.76e-05	1429	127	16	35140242
Pubmed	Embryo model completes gastrulation to neurulation and organogenesis.	SOX2 SOX17 EN1	6.96e-05	22	127	3	36007540
Pubmed	Sox9 is critical for suppression of neurogenesis but not initiation of gliogenesis in the cerebellum.	SOX2 SOX8 EN1	6.96e-05	22	127	3	25888505
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	FN1 KIF1A MAT2A SIPA1L3 APC RAD54L2 ARID1A FRY CS TXNDC15 DSCR9 SH3D19 EIF4G2 USP7 BRWD1	7.32e-05	1285	127	15	35914814
Pubmed	The role of FREM2 and FRAS1 in the development of congenital diaphragmatic hernia.	FREM1 FREM2	7.90e-05	4	127	2	29618029
Pubmed	FBI-1 functions as a novel AR co-repressor in prostate cancer cells.	NCOR1 ZBTB7A	7.90e-05	4	127	2	20812024
Pubmed	Deficiency of FRAS1-related extracellular matrix 1 (FREM1) causes congenital diaphragmatic hernia in humans and mice.	FREM1 FREM2	7.90e-05	4	127	2	23221805
Pubmed	Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions.	LIPG LPL	7.90e-05	4	127	2	20031538
Pubmed	Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels.	TNFSF12 MMP3	7.90e-05	4	127	2	21190865
Pubmed	Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.	FREM1 FREM2	7.90e-05	4	127	2	36495293
Pubmed	LRF-mediated Dll4 repression in erythroblasts is necessary for hematopoietic stem cell maintenance.	DLL4 ZBTB7A	7.90e-05	4	127	2	23134786
Interaction	BCOR interactions	SOX2 EGLN3 GATA1 SOX17 NCOR1 ZBTB7A CS ACTL8 USP7 EN1 RBFOX2	2.91e-06	302	125	11	int:BCOR
Interaction	ZBTB7C interactions	NCOR1 ZBTB7A USP7 ZBTB3	9.46e-06	22	125	4	int:ZBTB7C
Interaction	PKNOX1 interactions	KIF1A APC HOXD9 ZBTB3 MN1 FAM110B	1.20e-05	82	125	6	int:PKNOX1
Interaction	QKI interactions	SOX2 FN1 RBM45 BAG4 EIF4ENIF1 C8orf82 MED12 RBFOX2	2.47e-05	190	125	8	int:QKI
Interaction	SMARCA4 interactions	SOX2 TBX21 GATA1 SIK3 ARID1A NCOR1 ZBTB7A ARID1B KCNA3 ZMIZ2 USP7 BRWD1	3.10e-05	462	125	12	int:SMARCA4
Interaction	ZBBX interactions	FREM2 CELSR2 USP7 WDR62	3.90e-05	31	125	4	int:ZBBX
Interaction	ATXN1L interactions	SOX2 SOX17 MEIS3 RAD54L2 NCOR1 EN1 RBFOX2	4.21e-05	150	125	7	int:ATXN1L
Interaction	NXPH2 interactions	RHOT2 FREM2 IGF2R CELSR2	5.02e-05	33	125	4	int:NXPH2
GeneFamily	SRY-boxes	SOX2 SOX17 SOX8	8.57e-05	19	83	3	757
Coexpression	GSE17721_CTRL_VS_CPG_1H_BMDC_UP	R3HCC1 SDR42E1 NCOR1 ZBTB7A HOXB3 IGF2R ZMIZ2 SVIL	5.81e-06	200	126	8	M3756
Coexpression	DURAND_STROMA_S_UP	NPR2 DTX3L SVEP1 LOXL1 LPL LTBP2 EN1 MN1 FAM110B	1.53e-05	300	126	9	M2581
Coexpression	DURAND_STROMA_S_UP	NPR2 DTX3L SVEP1 LOXL1 LPL LTBP2 EN1 MN1 FAM110B	1.70e-05	304	126	9	MM1083
ToppCell	Adult-Mesenchymal\|Adult / Lineage, Cell type, age group and donor	BOC CACNA1C FN1 SVEP1 FREM1 HOXB3 SH3D19 LTBP2 TNXB	5.84e-09	198	127	9	26e55b409db2a1637c95fae7c54b0abea1ef550c
ToppCell	Adult-Mesenchymal-chondrocyte\|Adult / Lineage, Cell type, age group and donor	CACNA1C FN1 DLL4 TNS2 SVEP1 LIPG LTBP2 TNXB	1.91e-08	159	127	8	3f7305ee76447064b5c846c4f576360a2f7e0b7c
ToppCell	Control-Fibroblasts-Other_FB\|Control / group, cell type (main and fine annotations)	BOC CACNA1C FN1 SVEP1 HOXB3 TENM4 LTBP2 TNXB	6.74e-08	187	127	8	bd3739c4a52aa1ba5deffd778e113a9800f7e158
ToppCell	COVID-19-Fibroblasts-Other_FB\|COVID-19 / group, cell type (main and fine annotations)	BOC CACNA1C FN1 HOXB3 TENM4 SH3D19 LTBP2 RBFOX2	8.59e-08	193	127	8	e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell\|Adult / Lineage, Cell type, age group and donor	CACNA1C FN1 SVEP1 FREM1 HOXB3 SH3D19 LTBP2 TNXB	9.30e-08	195	127	8	61c9e09fc84d1012e472185d70ad0a06cee30d6e
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	BCAS3 SIPA1L3 AMBRA1 SIK3 ARID1B SHANK2 MBD5 RBFOX2	9.67e-08	196	127	8	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	BCAS3 SIPA1L3 AMBRA1 SIK3 ARID1B SHANK2 MBD5 RBFOX2	1.05e-07	198	127	8	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	COVID-19-kidney-AQP1+PLVAP+EC\|kidney / Disease (COVID-19 only), tissue and cell type	BOC CACNA1C FN1 DLL4 SOX17 STARD9 MN1 TNXB	1.05e-07	198	127	8	8689090bce9ab6e8f122426a404037e572c6713b
ToppCell	PCW_10-12-Mesenchymal\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	CACNA1C FN1 SVEP1 FREM1 HOXB3 LOXL1 LPL FAM110B	1.09e-07	199	127	8	a09292de4c4447b8eee55d401808e43b817321cc
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	BCAS3 SIPA1L3 AMBRA1 SIK3 ARID1B SHANK2 MBD5 RBFOX2	1.09e-07	199	127	8	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	Bronchial-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	BOC CACNA1C FN1 SVEP1 FREM1 HOXB3 LTBP2 TNXB	1.13e-07	200	127	8	389cc775c8419d90fb77cd794376d2160a7bf44e
ToppCell	Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1C FN1 SVEP1 FREM1 HOXB3 SH3D19 LTBP2 TNXB	1.13e-07	200	127	8	e8462395fee0a532d1e7ec7f1795f28c42af6541
ToppCell	TCGA-Breast-Solid_Tissue_Normal-Breast_normal_tissue-Breast_normal_tissue-3\|TCGA-Breast / Sample_Type by Project: Shred V9	DMGDH SVEP1 FREM1 KY STARD9 LPL TNXB	6.93e-07	174	127	7	7f8f5fafae08676d2b90cab9802c3c9320f1370e
ToppCell	TCGA-Breast-Solid_Tissue_Normal\|TCGA-Breast / Sample_Type by Project: Shred V9	DMGDH SVEP1 FREM1 KY STARD9 LPL TNXB	6.93e-07	174	127	7	e2f240d60bffbe8e6d60f0bb405b231bd3c96875
ToppCell	TCGA-Breast-Solid_Tissue_Normal-Breast_normal_tissue-Breast_normal_tissue\|TCGA-Breast / Sample_Type by Project: Shred V9	DMGDH SVEP1 FREM1 KY STARD9 LPL TNXB	6.93e-07	174	127	7	0f3ec0d0d4344e10c9b48adc9174123f6402dc51
ToppCell	TCGA-Breast-Solid_Tissue_Normal-Breast_normal_tissue\|TCGA-Breast / Sample_Type by Project: Shred V9	DMGDH SVEP1 FREM1 KY STARD9 LPL TNXB	6.93e-07	174	127	7	1aadbf2642b6d1320ceabd92e6ff59e11f16c315
ToppCell	Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CACNA1C NOG FN1 HOXB3 TENM4 LTBP2 MMP11	9.03e-07	181	127	7	d7e04e0ca549eac6d9b1192b6578f9b54943d54f
ToppCell	Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CACNA1C FN1 MEIS3 HOXB3 TENM4 LTBP2 ADGRA3	9.37e-07	182	127	7	ed6ae0fd8653f213fe29906a6a4e0729a62e1b75
ToppCell	facs-Mammary_Gland-Mammary_Gland-18m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 TNFSF12 SVEP1 LOXL1 LPL MMP3 TNXB	9.72e-07	183	127	7	5cfcd589a480e67654d3d94e71916f122150db10
ToppCell	facs-Mammary_Gland-Mammary_Gland-18m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 TNFSF12 SVEP1 LOXL1 LPL MMP3 TNXB	9.72e-07	183	127	7	c3ea8d3b916ffcaca3156e0d77a952724554c4ab
ToppCell	facs-Mammary_Gland-Mammary_Gland-18m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 TNFSF12 SVEP1 LOXL1 LPL MMP3 TNXB	9.72e-07	183	127	7	81003ddc24164959dd41bb12fcac72638789b8f2
ToppCell	COVID-19-Heart-Fib_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	FN1 SVEP1 TENM4 LOXL1 LTBP2 TNXB FAM110B	1.05e-06	185	127	7	8f95d8e591bf7379d13f5a0545b0cb49e2b1ab5d
ToppCell	facs-Limb_Muscle-Muscle_forelimb_and_hindlimb-18m-Mesenchymal-mesenchymal_stem_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 HSD3B7 LOXL1 MMP11 MN1 TNXB	1.08e-06	186	127	7	a7ab70b049742dfe7ee30557031bfac6412edf52
ToppCell	COVID-19-Heart-Fib_1\|COVID-19 / Disease (COVID-19 only), tissue and cell type	BOC SVEP1 FREM1 TENM4 LTBP2 TNXB FAM110B	1.16e-06	188	127	7	fe361215f4ba841aa5e1e581fb56f2f4d3ccd201
ToppCell	E16.5-samps-Mesenchymal\|E16.5-samps / Age Group, Lineage, Cell class and subclass	BOC FN1 SVEP1 FREM1 HOXB3 IGF2R LOXL1	1.16e-06	188	127	7	3f0f662be684e3a4c6652e636cc135a39a1d2790
ToppCell	facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-mesenchymal_stem_cell\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 SVIL LTBP2 MMP3 TNXB	1.25e-06	190	127	7	d13fd234caa3fc69d8a59bc0060cdacdf716ee55
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_2-SCMF\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CACNA1C FN1 HOXB3 TENM4 LOXL1 LTBP2 MMP11	1.34e-06	192	127	7	67e845e513e76e820f55e2f0d15eb16f2944d05c
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	BCAS3 SIK3 ARID1B SHANK2 SH3D19 SVIL MBD5	1.34e-06	192	127	7	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D231\|Adult / Lineage, Cell type, age group and donor	CACNA1C FN1 SVEP1 FREM1 HOXB3 LTBP2 TNXB	1.39e-06	193	127	7	ef2f456c094e6e3c6ee81e0668c953cb8d0e1c0a
ToppCell	COVID-19-Heart-Fib_1\|Heart / Disease (COVID-19 only), tissue and cell type	BOC FN1 SVEP1 FREM1 TENM4 LTBP2 TNXB	1.49e-06	195	127	7	f423baa36ac7cdc383c033e35a7d17e6bf913323
ToppCell	PCW_05-06-Mesenchymal\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	CACNA1C FN1 SVEP1 FREM1 HOXB3 TENM4 FAM110B	1.54e-06	196	127	7	dca52c57ba35d9395cdbca8b881f12ece721b10f
ToppCell	Children_(3_yrs)-Mesenchymal\|Children_(3_yrs) / Lineage, Cell type, age group and donor	BOC CACNA1C FN1 SVEP1 FREM1 SH3D19 TNXB	1.54e-06	196	127	7	bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	BOC SVEP1 TENM4 SVIL PTCH2 C1QTNF4 TNXB	1.59e-06	197	127	7	2744cc94883c5d0424677cf5093bbab622933e9b
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	BOC CACNA1C SVEP1 FREM1 TENM4 LTBP2 TNXB	1.59e-06	197	127	7	44673c38384453207871d3fd8e8ba9093cc06bc5
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	CACNA1C FN1 SVEP1 FREM1 LOXL1 SH3D19 LPL	1.59e-06	197	127	7	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	CACNA1C FN1 SVEP1 FREM1 LOXL1 SH3D19 LPL	1.59e-06	197	127	7	11a4c417f035e554431a8f03be13b5eefa3530c0
ToppCell	5'-GW_trimst-2-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	BOC SVEP1 TENM4 SVIL PTCH2 C1QTNF4 TNXB	1.70e-06	199	127	7	103f657132e830a0e5efeb745afb4b77c208a1fa
ToppCell	Mesenchymal\|World / Lineage, Cell type, age group and donor	BOC CACNA1C FN1 SVEP1 FREM1 HOXB3 TNXB	1.70e-06	199	127	7	4bac110c2b3609f6ee5d0e3275da0824a6240270
ToppCell	10x5'v1-week_14-16-Mesenchymal_myocytic-stroma-muscle_stem_cell\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	DTX3 SVEP1 TENM4 LOXL1 LPL LTBP2 RBFOX2	1.70e-06	199	127	7	6200618e029063486719479c41eaf31798bd13cf
ToppCell	Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	BOC CACNA1C FN1 SVEP1 KY TENM4 ADGRA3	1.70e-06	199	127	7	abd6117f8a3d7e798d8471c16d97b34aaf50fc9c
ToppCell	Parenchymal-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1C FN1 SVEP1 FREM1 HOXB3 LTBP2 TNXB	1.76e-06	200	127	7	cf433f9b43d7db07acaf70e060f8f77c974e72f3
ToppCell	Tracheal-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1C FN1 SVEP1 FREM1 STARD9 LTBP2 TNXB	1.76e-06	200	127	7	c318d14bd6fd6f42c597eb55ac9e2f48008aeb9b
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1C FN1 SVEP1 FREM1 HOXB3 LTBP2 TNXB	1.76e-06	200	127	7	311fab076f2ceb258e3970eb21e39344b894042a
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1C FN1 SVEP1 FREM1 HOXB3 LTBP2 TNXB	1.76e-06	200	127	7	34f52003988ce6329d8deeee1ab875fa77e01e9d
ToppCell	COVID-19_Mild-Classical_Monocyte-\|COVID-19_Mild / Disease condition and Cell class	DMGDH TNS2 HSD3B7 NUDT6 KCNA3 LIPG	2.10e-06	131	127	6	ae5eb9c013674b36987bf26d4f752dbb374f547b
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-Mast-Mast-D\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	GATA1 CS KCNA3 ASB16 ERICH6B SH3D19	2.61e-06	136	127	6	94eb78a4b8da307c07c2c4f05b8a14424f887579
ToppCell	Adult-Mesenchymal-chondrocyte-D122\|Adult / Lineage, Cell type, age group and donor	CACNA1C TNS2 SVEP1 NLGN3 SH3D19 ZBTB3	4.26e-06	148	127	6	81a1e6fdd942a612bf523c59b8b4974f6ca1fdce
ToppCell	Adult-Mesenchymal-chondrocyte-D231\|Adult / Lineage, Cell type, age group and donor	CACNA1C FN1 DLL4 SVEP1 LOXL1 LTBP2	7.69e-06	164	127	6	2ba57dce5f69a88f0d1e450b9780425e2d9ca7d4
ToppCell	TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-6\|TCGA-Liver / Sample_Type by Project: Shred V9	BOC CACNA1C SVEP1 PTCH2 LTBP2 TNXB	9.12e-06	169	127	6	e992530776cab922d0360b275fb9cb8bd0017b06
ToppCell	10x3'2.3-week_17-19-Neuro\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	KIF1A MEIS3 NLGN3 FREM2 MANEAL SH3D19	1.11e-05	175	127	6	bbce8b1a160b414c0bf643c21c4e5e78fbccb7e1
ToppCell	CV-Mild-6\|Mild / Virus stimulation, Condition and Cluster	MAN2B1 NLGN3 IGF2R STARD9 XPNPEP3 MBD5	1.11e-05	175	127	6	c4d530dbb37942427c9cd0a1533faeb6a3a45381
ToppCell	10x3'2.3-week_17-19-Neuro-stroma-schwann_cells\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	KIF1A MEIS3 NLGN3 FREM2 MANEAL SH3D19	1.11e-05	175	127	6	8b010220cdfb680ec839572f4933adfb85045ea6
ToppCell	10x3'2.3-week_17-19-Neuro-stroma\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	KIF1A MEIS3 NLGN3 FREM2 MANEAL SH3D19	1.11e-05	175	127	6	0b579aeadcc06be83627391c0b01bd8605fdbdf3
ToppCell	COVID-19-Heart-CM_3\|Heart / Disease (COVID-19 only), tissue and cell type	CACNA1C KCP FRY OXCT1 LPL SVIL	1.39e-05	182	127	6	287fcc3897ae08841f6f85ae6c9cef16f75b1dd1
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	BOC FN1 SVEP1 MN1 TNXB FAM110B	1.39e-05	182	127	6	3dfa9187e9d2bab1d199079d29209c4648220ada
ToppCell	COVID-19-Heart-Fib_+_EC_+_Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CACNA1C FN1 SVEP1 TENM4 LTBP2 TNXB	1.39e-05	182	127	6	fbd5e332df73bf7141c822fa67b76367dc962017
ToppCell	COVID-19-kidney-Mito-rich_EC\|kidney / Disease (COVID-19 only), tissue and cell type	BOC CACNA1C FN1 DLL4 MN1 TNXB	1.43e-05	183	127	6	3c4153479fc4ab2d073d92cee120480015555914
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.53e-05	185	127	6	3cd0686a14e734a0f243070ab939adcb4c454478
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.53e-05	185	127	6	00258f458cbf6d36449db95528a6b5038d731d2d
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.53e-05	185	127	6	a94694e226856bc5b168464f52d76004145717a5
ToppCell	COVID-19-Fibroblasts-Adventitial_FB\|COVID-19 / group, cell type (main and fine annotations)	BOC CACNA1C SVEP1 FREM1 SH3D19 TNXB	1.53e-05	185	127	6	a5aebf2b9b05b550d021272731d68af9a6b1229d
ToppCell	343B-Fibroblasts-Fibroblast-E-\|343B / Donor, Lineage, Cell class and subclass (all cells)	BOC EGLN3 NPR2 KCP HOXB3 TNXB	1.57e-05	186	127	6	1bac7825c2fe3e6cdff65026b09b9ccaa40fa27f
ToppCell	droplet-Kidney-KIDNEY-1m-Mesenchymal-fibroblast\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SVEP1 FREM1 LOXL1 MMP3 EN1 TNXB	1.57e-05	186	127	6	94d577dbb6bfacf50632e1fe8af041b35a1e6b23
ToppCell	343B-Fibroblasts-Fibroblast-E\|343B / Donor, Lineage, Cell class and subclass (all cells)	BOC EGLN3 NPR2 KCP HOXB3 TNXB	1.57e-05	186	127	6	59db239f1864a5d4f1570c93219dbd7ac5b6db35
ToppCell	Control-Fibroblasts-Alveolar_FB\|Control / group, cell type (main and fine annotations)	CACNA1C FN1 SVEP1 SH3D19 LTBP2 TNXB	1.62e-05	187	127	6	92d468dde81125d51daf7abd4703741abe1ab91c
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D175\|Adult / Lineage, Cell type, age group and donor	CACNA1C FN1 SVEP1 FREM1 LTBP2 TNXB	1.62e-05	187	127	6	e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f
ToppCell	Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CACNA1C FN1 HOXB3 TENM4 LTBP2 ADGRA3	1.62e-05	187	127	6	c104fbfef2d0bef64077ac721edf2379fd59d547
ToppCell	Control-Fibroblasts-Adventitial_FB\|Control / group, cell type (main and fine annotations)	BOC CACNA1C SVEP1 FREM1 MN1 TNXB	1.67e-05	188	127	6	706a26c372add839d947749f0521a0e1f5c9b0ec
ToppCell	Mesenchymal-myofibroblast_cell\|World / Lineage, Cell type, age group and donor	CACNA1C FN1 HOXB3 TENM4 LTBP2 ADGRA3	1.72e-05	189	127	6	44e37f88137bb249933eb615235b2cf2ae7f3925
ToppCell	droplet-Mammary_Gland-nan-21m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.72e-05	189	127	6	bc54ffd7bd1627a36747a80ce5139e4a69928400
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	AMBRA1 SIK3 FREM1 FRY ARID1B MBD5	1.72e-05	189	127	6	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	droplet-Mammary_Gland-nan-3m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.77e-05	190	127	6	bd0d68dc1b6f388190a6ba8a83b011619abe2bdd
ToppCell	droplet-Mammary_Gland-nan-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.77e-05	190	127	6	e275de94468872e70cf305b3b450823d4c9c5e3f
ToppCell	PND01-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	BOC KIF1A LOXL1 MMP3 MN1 TNXB	1.77e-05	190	127	6	947807863a9b247c301c6cf63d6fd5a2c8018e66
ToppCell	droplet-Mammary_Gland-nan-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.77e-05	190	127	6	ee2f4a55d2fd18b83e55399b5b5697a15a2d2e70
ToppCell	droplet-Mammary_Gland-nan-21m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.77e-05	190	127	6	f3ca94a31a35eed5fecf3c4b8c957e1bc4150158
ToppCell	Control-Fibroblasts\|Control / group, cell type (main and fine annotations)	CACNA1C FN1 SVEP1 FREM1 LTBP2 TNXB	1.77e-05	190	127	6	3a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell	droplet-Mammary_Gland-nan-21m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 LOXL1 LPL MMP3 TNXB	1.77e-05	190	127	6	c2cd1eb674162ee40502c3380b7245c85079c7ce
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Inner_Medullary_Collecting_Duct_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	BCAS3 SIPA1L3 KCP FREM1 HOXB3 SHANK2	1.83e-05	191	127	6	3e828cffa24ded19f591a7ed6c1fe88ad57fdcac
ToppCell	droplet-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	BOC CACNA1C SVEP1 LOXL1 MN1 TNXB	1.83e-05	191	127	6	b51e0f5d1b93f526160c904e9091313a5364f3a7
ToppCell	Control-Stromal_mesenchymal\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	BOC CACNA1C SVEP1 FREM1 TENM4 TNXB	1.83e-05	191	127	6	14057205ddb9b4bbc582d1358d13cf36d979a61b
ToppCell	PND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	BOC FN1 SVEP1 FREM1 IGF2R LOXL1	1.83e-05	191	127	6	e7c605b56934d1383237c1f946dbccef25d91368
ToppCell	facs-Trachea-nan-18m-Mesenchymal-fibroblast\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF12 SVEP1 LOXL1 MMP3 MN1 TNXB	1.83e-05	191	127	6	783e8c436de90623bb1bc4117270d60c8c8a9461
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CACNA1C SVEP1 FREM1 SH3D19 LTBP2 TNXB	1.83e-05	191	127	6	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	droplet-Kidney-nan-18m-Mesenchymal\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 FREM1 LOXL1 LTBP2 TNXB	1.88e-05	192	127	6	38d7a24ae205ef91ed2e0f402d8022f2a9cdb243
ToppCell	facs-Trachea-nan-18m-Mesenchymal-nan\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF12 SVEP1 LOXL1 MMP3 MN1 TNXB	1.88e-05	192	127	6	f388a336062880609724e91bf51bd0f9c4da2f69
ToppCell	droplet-Kidney-nan-18m-Mesenchymal-Stroma____fibroblast\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FN1 SVEP1 FREM1 LOXL1 LTBP2 TNXB	1.88e-05	192	127	6	04d155897ed075c359933080e36a4ab2150b6e9f
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CACNA1C SVEP1 FREM1 SH3D19 LTBP2 TNXB	1.88e-05	192	127	6	99ce9e3c4c50cf64ebb62145f2b5420efa0db309
ToppCell	facs-Trachea-nan-18m-Mesenchymal\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF12 SVEP1 LOXL1 MMP3 MN1 TNXB	1.88e-05	192	127	6	ceadfbce037bef15523916ba091bb6c0d752cce5
ToppCell	droplet-Lung-1m-Mesenchymal-fibroblast-adventitial_fibroblast\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	BOC SVEP1 LOXL1 MMP3 MN1 TNXB	1.88e-05	192	127	6	f9fb24457999dc9e751a099d7f995543b9330ad4
ToppCell	Adult-Mesenchymal-matrix_fibroblast_2_cell\|Adult / Lineage, Cell type, age group and donor	BOC MEIS3 SVEP1 HOXB3 MN1 TNXB	1.88e-05	192	127	6	d21f0f577156f17c899b08871046a26b88aea011
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	BCAS3 AMBRA1 ARMC9 SIK3 ARID1B RBFOX2	1.94e-05	193	127	6	779276e775cb2492e8dd36436295a536084a6415
ToppCell	COVID-19-Heart-CM_+_EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	CACNA1C FRY OXCT1 LPL SVIL CPVL	1.94e-05	193	127	6	dd5378a1ef8eb0eda9a3aae62f3c2f3a1402bda0
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Degenerative_Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FN1 SVEP1 LOXL1 LTBP2 MMP3 MMP11	1.94e-05	193	127	6	dc8e62df6121ee99b156aca6b1b3ae555739b6f2
ToppCell	facs-MAT-Fat-24m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF12 SVEP1 LOXL1 LPL MMP11 TNXB	1.94e-05	193	127	6	733f557bdc80293b40ccdf560f1675793df932d6
ToppCell	facs-MAT-Fat-24m-Mesenchymal\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF12 SVEP1 LOXL1 LPL MMP11 TNXB	1.94e-05	193	127	6	eb3c46b6fb06dc8708dc3032189b47ed93ee2357
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	CACNA1C FN1 SVEP1 FREM1 SH3D19 TNXB	1.94e-05	193	127	6	99525545552b371c86b18b6ea6f4897dc6e9a9ec
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CACNA1C FN1 HOXB3 TENM4 LTBP2 MMP11	1.94e-05	193	127	6	5de87fc94a6e58899ef4124cf4887ed3ff96163a
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Degenerative_Fibroblast-Degenerative_Fibroblast_119\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FN1 SVEP1 LOXL1 LTBP2 MMP3 MMP11	1.94e-05	193	127	6	e2ee077fd381bd906e6b4329f22e7d106e422a7f
ToppCell	facs-MAT-Fat-24m-Mesenchymal-mesenchymal_progenitor\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFSF12 SVEP1 LOXL1 LPL MMP11 TNXB	1.94e-05	193	127	6	b45cd02081f97904eaea2d013e1fa980505d060b
Drug	valerate	BOC FN1 OXCT2 NUDT6 OXCT1 EIF4G2 MMP3 MMP11	9.38e-08	102	125	8	CID000007991
Drug	S-(+)-ibuprofen [51146-56-6]; Down 200; 19.4uM; MCF7; HT_HG-U133A	NPR2 FN1 UGGT1 APC ANKLE2 NUDT6 SVIL MTCL1 DNMBP	1.46e-06	197	125	9	5311_DN
Drug	Amikacin hydrate [37517-28-5]; Down 200; 6.6uM; MCF7; HT_HG-U133A	NPR2 APC AMBRA1 ARID1A ANKLE2 ZBTB7A LOXL1 SVIL RBFOX2	1.52e-06	198	125	9	5314_DN
Drug	AC1NS1NJ	OXCT2 CS OXCT1	1.60e-06	5	125	3	CID005327101
Drug	methyl 3-mercaptopropionate	BOC OXCT2 OXCT1	5.56e-06	7	125	3	CID000018050
Drug	oxfenicine	OXCT2 CS OXCT1 LPL	7.07e-06	23	125	4	CID000036143
Drug	Domperidone maleate; Down 200; 7.4uM; HL60; HT_HG-U133A	MAN2B1 FN1 RHOT2 RAD54L2 NCOR1 SVIL USP7 RBFOX2	1.30e-05	196	125	8	1301_DN
Drug	octamethylcyclotetrasiloxane	FN1 OXCT2 CS	1.32e-05	9	125	3	CID000011169
Drug	16, 16-dimethylprostaglandin E2 methyl acetate solution; Down 200; 10uM; PC3; HT_HG-U133A	NPR2 BCAS3 SIPA1L3 ZBTB7A CELSR2 ZMIZ2 CCSER2 RBFOX2	1.40e-05	198	125	8	6592_DN
Drug	Megestrol acetate [595-33-5]; Down 200; 10.4uM; HL60; HT_HG-U133A	FN1 KIF1A APC SVEP1 USP7 LTBP2 MMP3 WDR62	1.40e-05	198	125	8	3091_DN
Drug	Ricinine [524-40-3]; Down 200; 24.4uM; PC3; HT_HG-U133A	NPR2 FN1 ARMC9 RHOT2 RAD54L2 LIPG EIF4G2 CCSER2	1.45e-05	199	125	8	5725_DN
Drug	Leflunomide [75706-12-6]; Down 200; 14.8uM; HL60; HT_HG-U133A	NPR2 KIF1A SIPA1L3 CR1 KCNA3 XPNPEP3 RBFOX2 BRWD1	1.45e-05	199	125	8	2539_DN
Drug	Tobramycin [32986-56-4]; Up 200; 8.6uM; HL60; HT_HG-U133A	FN1 KIF1A SHANK2 CELSR2 LIPG ZMIZ2 XPNPEP3 LTBP2	1.51e-05	200	125	8	2481_UP
Drug	benzoyl-S-CoA	MAT1A MAT2A OXCT2 APC OXCT1	1.67e-05	58	125	5	CID000122174
Drug	citramalate	OXCT2 CS OXCT1	2.58e-05	11	125	3	CID000001081
Drug	AC1NQZW7	OXCT2 OXCT1	2.99e-05	2	125	2	CID005282334
Drug	CPD-627	OXCT2 OXCT1	2.99e-05	2	125	2	CID000439367
Drug	AC1LCVNZ	OXCT2 OXCT1	2.99e-05	2	125	2	CID000656887
Drug	naphthyl-2-methyl-succinate	OXCT2 OXCT1	2.99e-05	2	125	2	CID000656886
Drug	AC1L3UHX	OXCT2 OXCT1	2.99e-05	2	125	2	CID000095516
Drug	2-amino-4-methylthio-3-butenoic acid	MAT1A MAT2A	2.99e-05	2	125	2	ctd:C083253
Drug	S010	NOG ARID1A SHANK2	3.43e-05	12	125	3	CID006452892
Drug	p-nitrophenyl caprylate	BOC SLC6A7 LPL	4.44e-05	13	125	3	CID000097416
Drug	AC1L970B	OXCT2 CS OXCT1	5.63e-05	14	125	3	CID000439266
Drug	3-phenyllactic acid	OXCT2 OXCT1 LOXL1 LPL	6.14e-05	39	125	4	CID000003848
Drug	CoA-oxalate	OXCT2 SLC6A7 OXCT1	8.59e-05	16	125	3	CID000000973
Drug	L-2-amino-4-methylthio-cis-but-3-enoic acid	MAT1A MAT2A	8.94e-05	3	125	2	CID006439623
Drug	p-azidobenzoyl-CoA	OXCT2 OXCT1	8.94e-05	3	125	2	CID000194163
Drug	benzylphosphate	MAT1A MAT2A	8.94e-05	3	125	2	CID000074359
Drug	Tranexamic acid [1197-18-8]; Down 200; 25.4uM; PC3; HT_HG-U133A	FN1 APC ARID1A LIPG EIF4G2 USP7 BRWD1	1.00e-04	194	125	7	5762_DN
Drug	Alsterpaullone; Up 200; 10uM; MCF7; HT_HG-U133A	FN1 KIF1A ZBTB7A SHANK2 LTBP2 MN1 WDR62	1.00e-04	194	125	7	7051_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A	FN1 AMBRA1 ARID1A NCOR1 SVIL XPNPEP3 CCSER2	1.03e-04	195	125	7	1163_DN
Drug	radicicol; Down 200; 0.1uM; MCF7; HG-U133A	FN1 SIPA1L3 CEACAM3 RRP12 HHIPL2 CCSER2 RBFOX2	1.03e-04	195	125	7	489_DN
Drug	Androsterone [53-41-8]; Down 200; 13.8uM; HL60; HT_HG-U133A	AMBRA1 RHOT2 RAD54L2 ARID1A ITGAL SVIL XPNPEP3	1.03e-04	195	125	7	1296_DN
Drug	Harmaline hydrochloride dihydrate [6027-98-1]; Up 200; 14uM; MCF7; HT_HG-U133A	FN1 RAD54L2 TENM4 ACTL8 LTBP2 MMP3 MED12	1.03e-04	195	125	7	2805_UP
Drug	Hippeastrine hydrobromide [22352-41-6]; Down 200; 10uM; PC3; HT_HG-U133A	AMBRA1 CEMIP2 NCOR1 SHANK2 ZBTB3 DNMBP BRWD1	1.03e-04	195	125	7	7381_DN
Drug	PNU-0230031 [267429-39-0]; Down 200; 1uM; PC3; HT_HG-U133A	NPR2 SIPA1L3 APC LIPG ZMIZ2 ZBTB3 CYB5R2	1.03e-04	195	125	7	3735_DN
Drug	Desipramine hydrochloride [58-28-6]; Up 200; 13.2uM; MCF7; HT_HG-U133A	NPR2 BAG4 ARID1A CR1 ZMIZ2 LTBP2 FAM110B	1.03e-04	195	125	7	3212_UP
Drug	Todralazine hydrochloride [3778-76-5]; Down 200; 14.8uM; HL60; HT_HG-U133A	FN1 SIPA1L3 APC RHOT2 SIK3 FRY MED12	1.07e-04	196	125	7	1841_DN
Drug	Chenodiol [474-25-9]; Up 200; 10.2uM; PC3; HT_HG-U133A	SIPA1L3 APC RHOT2 ZBTB7A RRP12 CCSER2 FAM110B	1.07e-04	196	125	7	7310_UP
Drug	Thiamine hydrochloride [67-03-8]; Up 200; 11.8uM; HL60; HG-U133A	FN1 AMBRA1 RHOT2 RRP12 XPNPEP3 CCSER2 RBFOX2	1.07e-04	196	125	7	1744_UP
Drug	AC1L3M3D	MAT2A ARMC9 SHANK2 TNXB	1.08e-04	45	125	4	CID000091445
Drug	3'-sialyl LewisX	SOX2 BOC FN1 TBX21 CEACAM3 ITGAL MMP11	1.10e-04	197	125	7	CID000643990
Drug	Cefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; HL60; HT_HG-U133A	SIPA1L3 CELSR2 ZMIZ2 MMP3 DNMBP RBFOX2 WDR62	1.10e-04	197	125	7	2564_UP
Drug	N-Acetyl-L-leucine [1188-21-2]; Up 200; 23uM; PC3; HT_HG-U133A	CEACAM7 APC DGKA ITGAL ZMIZ2 EIF4G2 BRWD1	1.10e-04	197	125	7	4622_UP
Drug	Xamoterol hemifumarate [73210-73-8]; Down 200; 5uM; MCF7; HT_HG-U133A	EGLN3 APC RAD54L2 CR1 ACTL8 ZMIZ2 WDR62	1.10e-04	197	125	7	3401_DN
Drug	N6-methyladenosine [1867-73-8]; Down 200; 14.2uM; PC3; HT_HG-U133A	KIF1A BCAS3 ARMC9 EIF4G2 ZBTB3 EN1 MN1	1.10e-04	197	125	7	6732_DN
Drug	LY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A	KIF1A SIPA1L3 TNS2 ANKLE2 CEMIP2 MED12 RBFOX2	1.10e-04	197	125	7	6935_DN
Drug	Benzathine benzylpenicillin [5928-84-7]; Down 200; 4.2uM; PC3; HT_HG-U133A	NPR2 KIF1A SIPA1L3 CEACAM3 CEACAM7 MMP3 EN1	1.10e-04	197	125	7	4022_DN
Drug	Hydroflumethiazide [135-09-1]; Up 200; 12uM; HL60; HT_HG-U133A	FN1 KIF1A SIPA1L3 APC ZBTB7A KCNA3 DNMBP	1.14e-04	198	125	7	1851_UP
Drug	Phthalylsulfathiazole [85-73-4]; Up 200; 10uM; MCF7; HT_HG-U133A	FN1 GATA1 SVEP1 TENM4 SHANK2 CYB5R2 WDR62	1.14e-04	198	125	7	5614_UP
Drug	Adenosine 5'-monophosphate monohydrate [18422-05-4]; Up 200; 11uM; MCF7; HT_HG-U133A	FN1 SIPA1L3 BAG4 APC SHANK2 ZMIZ2 PTCH2	1.14e-04	198	125	7	3237_UP
Drug	Ondansetron Hydrochloride [103639-04-9]; Down 200; 12.2uM; HL60; HT_HG-U133A	NPR2 TNS2 ARMC9 ARID1A CELSR2 SVIL CYB5R2	1.14e-04	198	125	7	6153_DN
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; HL60; HT_HG-U133A	APC ARID1A ACTL8 ZMIZ2 RRP12 SVIL HHIPL2	1.14e-04	198	125	7	2197_UP
Drug	Etofylline [519-37-9]; Up 200; 17.8uM; PC3; HT_HG-U133A	EGLN3 FN1 APC ZMIZ2 RRP12 MMP3 MMP11	1.17e-04	199	125	7	5048_UP
Drug	Triamcinolone [124-94-7]; Down 200; 10.2uM; MCF7; HT_HG-U133A	FN1 SIPA1L3 TNS2 ARMC9 RHOT2 ZBTB7A IGF2R	1.17e-04	199	125	7	7192_DN
Drug	Idazoxan hydrochloride [79944-56-2]; Down 200; 16.6uM; MCF7; HT_HG-U133A	SOX2 KIF1A SIPA1L3 BAG4 ACTL8 SUOX FAM110B	1.17e-04	199	125	7	6465_DN
Drug	Sparteine (-) [90-39-1]; Up 200; 17uM; PC3; HT_HG-U133A	NPR2 CEACAM3 CEACAM7 APC SVEP1 HOXD9 CYB5R2	1.17e-04	199	125	7	4568_UP
Drug	Karakoline [39089-30-0]; Down 200; 10.6uM; HL60; HT_HG-U133A	FN1 CEMIP2 RRP12 CCSER2 LTBP2 RBFOX2 WDR62	1.17e-04	199	125	7	2203_DN
Drug	Nalbuphine hydrochloride [23277-43-2]; Up 200; 10.2uM; PC3; HT_HG-U133A	CEACAM3 CEACAM7 ARID1A ITGAL NUDT6 LPL PTCH2	1.17e-04	199	125	7	5820_UP
Drug	Mometasone furoate [83919-23-7]; Down 200; 7.6uM; MCF7; HT_HG-U133A	APC RHOT2 ANKLE2 NCOR1 NUDT6 USP7 MED12	1.17e-04	199	125	7	5541_DN
Drug	Methylergometrine maleate [113-42-8]; Up 200; 8.8uM; MCF7; HT_HG-U133A	FN1 CEACAM7 APC ARID1A ZMIZ2 LTBP2 MMP11	1.21e-04	200	125	7	3222_UP
Drug	coproporphyrinogen I	RBM45 OXCT2 OXCT1	1.24e-04	18	125	3	CID000440776
Drug	D3273	EGLN3 FN1 MAT2A ACTL8 MMP3	1.71e-04	94	125	5	CID005464587
Drug	sinefungin	MAT1A MAT2A CS NUDT6	1.77e-04	51	125	4	CID000065482
Drug	sodium chlorate	FN1 NUDT6 LIPG LPL	1.77e-04	51	125	4	CID000516902
Drug	AC1L2LUF	OXCT2 OXCT1	1.78e-04	4	125	2	CID000074406
Drug	NSC-187732	MAT1A MAT2A	1.78e-04	4	125	2	CID000302526
Drug	vinthionine	MAT1A MAT2A	1.78e-04	4	125	2	CID000055145
Drug	seleno-DL-ethionine	MAT1A MAT2A	1.78e-04	4	125	2	CID000145924
Disease	phospholipids in medium HDL measurement	SIK3 ARID1A CELSR2 LIPG LPL	3.15e-06	55	121	5	EFO_0022295
Disease	total lipids in medium HDL measurement	SIK3 ARID1A CELSR2 LIPG LPL	4.11e-06	58	121	5	EFO_0022310
Disease	cholesterol in medium HDL measurement	SIK3 ARID1A CELSR2 LIPG LPL	4.48e-06	59	121	5	EFO_0021903
Disease	forced expiratory volume	BOC DMGDH TNFSF12 BCAS3 VTA1 SVEP1 NCOR1 HOXB3 SUOX LOXL1 MTCL1 EN1 MN1 TNXB	4.59e-06	789	121	14	EFO_0004314
Disease	total lipids in VLDL measurement	SIK3 ARID1A IGF2R CELSR2 LPL	4.87e-06	60	121	5	EFO_0022314
Disease	phospholipids in HDL measurement	SIK3 ARID1A CELSR2 LIPG LPL	5.28e-06	61	121	5	EFO_0022293
Disease	triglycerides in medium LDL measurement	SIK3 ARID1A IGF2R CELSR2 LPL	5.73e-06	62	121	5	EFO_0022322
Disease	cholesteryl esters to total lipids in medium VLDL percentage	DMGDH TENT4A SIK3 CELSR2 LPL	6.70e-06	64	121	5	EFO_0022253
Disease	cholesterol in large VLDL measurement	SIK3 ARID1A IGF2R CELSR2 LPL	7.24e-06	65	121	5	EFO_0021902
Disease	cholesterol in very large VLDL measurement	SIK3 ARID1A IGF2R CELSR2 LPL	7.24e-06	65	121	5	EFO_0022230
Disease	free cholesterol to total lipids in large LDL percentage	DMGDH TENT4A SIK3 CELSR2 LPL	1.37e-05	74	121	5	EFO_0022280
Disease	cholesteryl esters to total lipids in medium LDL percentage	SIK3 IGF2R LIPG LPL	1.60e-05	37	121	4	EFO_0022252
Disease	Vesicoureteral Reflux 1	SOX17 TNXB	1.67e-05	2	121	2	C4551858
Disease	Marles Greenberg Persaud syndrome	FREM1 FREM2	1.67e-05	2	121	2	C1855425
Disease	very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	DMGDH SIK3 ARID1A IGF2R TENM4 CELSR2 LIPG LPL	2.79e-05	291	121	8	EFO_0008317, EFO_0020946
Disease	triglycerides in large LDL measurement	SIK3 IGF2R CELSR2 LPL	2.93e-05	43	121	4	EFO_0022319
Disease	cholesteryl esters to total lipids in small HDL percentage	SIK3 CELSR2 LIPG LPL	2.93e-05	43	121	4	EFO_0022254
Disease	Malignant neoplasm of breast	BOC TFAP2D FN1 DLL4 DTX3 DTX3L SIK3 ARID1A NCOR1 ARID1B NSUN6 TXNDC15 MMP3 ZBTB3 MED12	3.48e-05	1074	121	15	C0006142
Disease	phospholipids:total lipids ratio	DMGDH SIK3 ARID1A IGF2R CELSR2 LIPG LPL	4.37e-05	227	121	7	EFO_0020946
Disease	Familial vesicoureteral reflux	SOX17 TNXB	4.99e-05	3	121	2	cv:C4706552
Disease	Familial vesicoureteral reflux	SOX17 TNXB	4.99e-05	3	121	2	C4706552
Disease	Vesicoureteral reflux	SOX17 TNXB	4.99e-05	3	121	2	cv:C0042580
Disease	triglycerides to total lipids in medium LDL percentage	TENT4A SIK3 CELSR2 LPL	5.35e-05	50	121	4	EFO_0022334
Disease	cholesteryl esters to total lipids in IDL percentage	SIK3 ARID1A LIPG LPL	5.35e-05	50	121	4	EFO_0022247
Disease	total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement	TENT4A SIK3 CELSR2 LPL	5.79e-05	51	121	4	EFO_0004340, EFO_0004348, EFO_0004468, EFO_0004530, EFO_0004574, EFO_0004612, EFO_0006335, EFO_0006336, EFO_0007928
Disease	triglycerides to total lipids in large LDL percentage	TENT4A SIK3 CELSR2 LPL	5.79e-05	51	121	4	EFO_0022331
Disease	cholesterol to total lipids in small HDL percentage	SIK3 CELSR2 LIPG LPL	5.79e-05	51	121	4	EFO_0022240
Disease	phospholipids in medium VLDL measurement	SIK3 IGF2R CELSR2 LPL	6.26e-05	52	121	4	EFO_0022154
Disease	total lipids in medium VLDL	SIK3 IGF2R CELSR2 LPL	7.26e-05	54	121	4	EFO_0022153
Disease	triglycerides in medium HDL measurement	SIK3 CELSR2 LIPG LPL	7.26e-05	54	121	4	EFO_0022321
Disease	triglycerides in medium VLDL measurement	SIK3 ARID1A CELSR2 LPL	7.81e-05	55	121	4	EFO_0022155
Disease	cholesterol to total lipids in large HDL percentage	DMGDH SIK3 CELSR2 LPL	7.81e-05	55	121	4	EFO_0022234
Disease	apolipoprotein A 1 measurement, apolipoprotein B measurement	SIK3 ARID1A CELSR2 LIPG LPL	8.12e-05	107	121	5	EFO_0004614, EFO_0004615
Disease	triglycerides in LDL measurement	SIK3 IGF2R CELSR2 LPL	8.38e-05	56	121	4	EFO_0022320
Disease	cholesterol to total lipids in large LDL percentage	TENT4A SIK3 CELSR2 LPL	8.38e-05	56	121	4	EFO_0022235
Disease	cholesteryl ester measurement	SDR42E1 SIK3 ARID1A IGF2R CELSR2 LIPG LPL	9.51e-05	257	121	7	EFO_0010351
Disease	triglycerides in IDL measurement	SIK3 IGF2R CELSR2 LPL	9.62e-05	58	121	4	EFO_0022149
Disease	triglycerides to total lipids in small VLDL percentage	DMGDH SIK3 CELSR2 LPL	9.62e-05	58	121	4	EFO_0022338
Disease	free cholesterol in medium HDL measurement	SIK3 ARID1A LIPG LPL	9.62e-05	58	121	4	EFO_0022267
Disease	Fraser syndrome (implicated_via_orthology)	FREM1 FREM2	9.95e-05	4	121	2	DOID:0090001 (implicated_via_orthology)
Disease	Vesico-Ureteral Reflux	SOX17 TNXB	9.95e-05	4	121	2	C0042580
Disease	very low density lipoprotein cholesterol measurement	SIK3 ARID1A IGF2R CELSR2 LIPG LPL BRWD1	1.02e-04	260	121	7	EFO_0008317
Disease	triglycerides to total lipids in small LDL percentage	DMGDH SIK3 CELSR2 LPL	1.03e-04	59	121	4	EFO_0022337
Disease	phospholipids in VLDL measurement	SIK3 IGF2R CELSR2 LPL	1.03e-04	59	121	4	EFO_0022301
Disease	cholesterol to total lipids in IDL percentage	TENT4A SIK3 ARID1A LPL	1.10e-04	60	121	4	EFO_0022233
Disease	cardiovascular disease	TFAP2D BCAS3 SVEP1 FREM1 HOXB3 CELSR2 LPL C1QTNF4 FAM110B	1.16e-04	457	121	9	EFO_0000319
Disease	triglycerides in small VLDL measurement	DMGDH SIK3 ARID1A LPL	1.17e-04	61	121	4	EFO_0022145
Disease	free cholesterol in VLDL measurement	SIK3 IGF2R CELSR2 LPL	1.17e-04	61	121	4	EFO_0022276
Disease	eosinophil count	TENT4A SIPA1L3 TBX21 GATA1 KCP SIK3 ANKLE2 SVEP1 ZBTB7A SUOX LPL RRP12 USP7 LTBP2 MBD5 TNXB GABBR1	1.23e-04	1488	121	17	EFO_0004842
Disease	omega-3 polyunsaturated fatty acid measurement	CELSR2 LIPG ZMIZ2 LPL BRWD1	1.29e-04	118	121	5	EFO_0010119
Disease	triglycerides to total lipids in IDL percentage	DMGDH SIK3 CELSR2 LPL	1.33e-04	63	121	4	EFO_0022329
Disease	triglycerides to total lipids in medium VLDL percentage	DMGDH SIK3 CELSR2 LPL	1.33e-04	63	121	4	EFO_0022335
Disease	total lipids in HDL measurement	SIK3 ARID1A LIPG LPL	1.33e-04	63	121	4	EFO_0022307
Disease	cholesterol to total lipids in medium VLDL percentage	DMGDH SIK3 CELSR2 LPL	1.33e-04	63	121	4	EFO_0022239
Disease	triglyceride measurement, high density lipoprotein cholesterol measurement	DMGDH SIK3 IGF2R TENM4 CELSR2 LIPG LPL	1.41e-04	274	121	7	EFO_0004530, EFO_0004612
Disease	triglycerides in small LDL measurement	SIK3 ARID1A CELSR2 LPL	1.50e-04	65	121	4	EFO_0022323
Disease	FEV/FEC ratio	BOC NOG BCAS3 DCBLD1 VTA1 CEMIP2 FREM2 SUOX SVIL CCSER2 LTBP2 MTCL1 CPVL MN1 TNXB	1.55e-04	1228	121	15	EFO_0004713
Disease	vesicoureteral reflux (is_implicated_in)	SOX17 TNXB	1.65e-04	5	121	2	DOID:9620 (is_implicated_in)
Disease	MENTAL RETARDATION, AUTOSOMAL DOMINANT 12	ARID1A ARID1B	1.65e-04	5	121	2	C3281201
Disease	vital capacity	NOG FN1 KIF1A TNFSF12 VTA1 SVEP1 KY NCOR1 ZBTB7A NUDT6 LOXL1 LTBP2 MTCL1 EN1 TNXB	1.66e-04	1236	121	15	EFO_0004312
Disease	total lipids in small VLDL	SIK3 IGF2R CELSR2 LPL	1.69e-04	67	121	4	EFO_0022148
Disease	total lipids in large VLDL	SIK3 ARID1A CELSR2 LPL	1.69e-04	67	121	4	EFO_0022175
Disease	cholesterol to total lipids in very small VLDL percentage	DMGDH SIK3 CELSR2 LPL	1.69e-04	67	121	4	EFO_0022245
Disease	non-high density lipoprotein cholesterol measurement	FN1 HLA-H DTX3L ARID1A HOXB3 IGF2R CELSR2 LIPG LPL RBFOX2 BRWD1	1.75e-04	713	121	11	EFO_0005689
Disease	free cholesterol in large VLDL measurement	SIK3 ARID1A CELSR2 LPL	1.79e-04	68	121	4	EFO_0022265
Disease	sexual dimorphism measurement	NOG KIF1A TNFSF12 R3HCC1 APC RHOT2 SIK3 RAD54L2 ARID1A FAM83C LIPG LOXL1 LPL LTBP2	1.81e-04	1106	121	14	EFO_0021796
Disease	esterified cholesterol measurement	SIK3 IGF2R CELSR2 LIPG LPL	1.89e-04	128	121	5	EFO_0008589
Disease	total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality, cancer	TENT4A SIK3 CELSR2 LPL	1.89e-04	69	121	4	EFO_0000275, EFO_0000400, EFO_0000712, EFO_0001645, EFO_0003144, EFO_0004340, EFO_0004348, EFO_0004352, EFO_0004468, EFO_0004530, EFO_0004574, EFO_0004612, EFO_0006335, EFO_0006336, EFO_0007928, MONDO_0004992
Disease	triglycerides to total lipids in very small VLDL percentage	DMGDH SIK3 CELSR2 LPL	1.89e-04	69	121	4	EFO_0022341
Disease	choline measurement	TENT4A SIK3 CELSR2 LIPG LPL	2.03e-04	130	121	5	EFO_0010116
Disease	Manic Disorder	CACNA1C TENM4 SHANK2 STARD9	2.11e-04	71	121	4	C0024713
Disease	creatinine measurement	DMGDH NOG BCAS3 SIPA1L3 ARMC9 ARID1A FRY IGF2R CELSR2 LPL SVIL MMP11 MBD5	2.30e-04	995	121	13	EFO_0004518
Disease	free cholesterol to total lipids in small VLDL percentage	DMGDH SIK3 CELSR2 LPL	2.61e-04	75	121	4	EFO_0022287
Disease	free cholesterol measurement, very low density lipoprotein cholesterol measurement	SIK3 ARID1A IGF2R CELSR2 LIPG LPL	2.67e-04	215	121	6	EFO_0008317, EFO_0008591
Disease	phospholipid measurement	TENT4A SIK3 LIPG LPL C1QTNF4	2.86e-04	140	121	5	EFO_0004639
Disease	Bladder Neoplasm	SOX2 ARID1A NCOR1 LOXL1 USP7	2.86e-04	140	121	5	C0005695
Disease	Malignant neoplasm of urinary bladder	SOX2 ARID1A NCOR1 LOXL1 USP7	2.96e-04	141	121	5	C0005684
Disease	very low density lipoprotein cholesterol measurement, lipid measurement	ARID1A IGF2R CELSR2 LIPG LPL BRWD1	3.02e-04	220	121	6	EFO_0004529, EFO_0008317
Disease	Manic	CACNA1C TENM4 SHANK2 STARD9	3.04e-04	78	121	4	C0338831
Disease	monounsaturated fatty acids; 16:1, 18:1 measurement	SIK3 IGF2R LIPG LPL	3.04e-04	78	121	4	EFO_0022187
Disease	Depression, Bipolar	CACNA1C TENM4 SHANK2 STARD9	3.19e-04	79	121	4	C0005587
Disease	Glioblastoma	FN1 APC NCOR1 ZBTB7A	3.19e-04	79	121	4	C0017636
Disease	fish oil supplement exposure measurement, high density lipoprotein cholesterol measurement	SIK3 LPL	3.46e-04	7	121	2	EFO_0004612, EFO_0600007
Disease	very low density lipoprotein cholesterol measurement, phospholipid measurement	SIK3 ARID1A IGF2R CELSR2 LPL BRWD1	3.74e-04	229	121	6	EFO_0004639, EFO_0008317
Disease	Breast Carcinoma	FN1 DLL4 DTX3 ARID1A NCOR1 ARID1B NSUN6 MMP3 MED12	3.87e-04	538	121	9	C0678222
Disease	coronary artery disease	FN1 KIF1A TENT4A BCAS3 MAT2A SVEP1 IGF2R CELSR2 LIPG LOXL1 LPL TNXB GABBR1 ATG16L2	3.93e-04	1194	121	14	EFO_0001645
Disease	Giant Cell Glioblastoma	FN1 APC NCOR1 ZBTB7A	4.03e-04	84	121	4	C0334588
Disease	lipoprotein measurement, phospholipid measurement	TENT4A CELSR2 LIPG FAM110B	4.22e-04	85	121	4	EFO_0004639, EFO_0004732
Disease	low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	SIK3 CELSR2 LIPG LPL ATG16L2	4.30e-04	153	121	5	EFO_0004611, EFO_0020946
Disease	low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	SIK3 IGF2R CELSR2 LIPG LPL	4.30e-04	153	121	5	EFO_0004611, EFO_0020944
Disease	cholesteryl esters to total lipids in very large HDL percentage	SIK3 CELSR2 LPL	4.35e-04	36	121	3	EFO_0022257
Disease	fatty acid measurement	DMGDH TENT4A SIK3 IGF2R CELSR2 LIPG LPL BRWD1	4.48e-04	436	121	8	EFO_0005110
Disease	Unilateral agenesis of kidney	FREM1 FREM2	4.59e-04	8	121	2	C0266294
Disease	very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	DMGDH SIK3 IGF2R CELSR2 LIPG LPL	4.69e-04	239	121	6	EFO_0008317, EFO_0020945
Disease	free cholesterol to total lipids in large VLDL percentage	CELSR2 LIPG LPL	4.72e-04	37	121	3	EFO_0022281
Disease	vitamin D measurement	MAT1A SDR42E1 SIK3 SHANK2 CELSR2 LIPG FAM110B	4.86e-04	336	121	7	EFO_0004631
Disease	cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement	DMGDH SIK3 IGF2R CELSR2 LIPG LPL	5.12e-04	243	121	6	EFO_0004612, EFO_0020944
Disease	chronic obstructive pulmonary disease	BOC TNFSF12 BCAS3 VTA1 TENM4 SVIL MTCL1 MMP3 MN1 GABBR1	5.53e-04	688	121	10	EFO_0000341
Disease	HEPATOCELLULAR CARCINOMA	APC IGF2R	5.89e-04	9	121	2	114550
Disease	Mental deterioration	CACNA1C CR1	5.89e-04	9	121	2	C0234985

Protein segments in the cluster

Peptide	Gene	Start	Entry
EPGRAGGSHQEQPPY	BAG4	81	O95429
PDGTGQIHYPSGNLA	ERICH6B	491	Q5W0A0
GLGSPGRYSPVHGSQ	ANKLE2	911	Q86XL3
RGHSIGGAPEQRYQI	ATG16L2	301	Q8NAA4
NGRLYHPAPERAGGV	C8orf82	151	Q6P1X6
GYGLTRVQPFHQGRP	ACTL8	151	Q9H568
EVVGPNTKGHPFYRG	HSD3B7	131	Q9H2F3
HGSGIYPGNPQDERK	ADGRA3	381	Q8IWK6
YGARAEVPNGAGHTP	ASB16	306	Q96NS5
LHGAPQYALGAPGAT	C1QTNF4	136	Q9BXJ3
HTLDYNLAPGPLGRG	DLL4	611	Q9NR61
HPEIVGYSVPGRNGQ	DNMBP	1471	Q6XZF7
DRRHEPYGQQYPGQG	ARID1B	1406	Q8NFD5
LSVQHQVYAREPGGP	NPR2	196	P20594
QVYAREPGGPEQATH	NPR2	201	P20594
APGPAHNGRETIYPN	CEACAM7	91	Q14002
YGQQRAEGNLGPRLH	CELSR2	1721	Q9HCU4
SPHAGYPAGGLLRSQ	RAD54L2	1421	Q9Y4B4
PYAGIFHERGQPGLA	AMBRA1	816	Q9C0C7
RGTSHVFPINPYGGQ	BCAS3	426	Q9H6U6
PGNGTGYVRHVDNPN	EGLN3	126	Q9H6Z9
GSQYGMHPDQRLLPG	TFAP2D	151	Q7Z6R9
PSRYHGPRPISNQGA	R3HCC1	101	Q9Y3T6
LHGFQYPPGNRIGVS	RBM45	306	Q8IUH3
YHGPGNLGIRPDQTS	CYB5R2	126	Q6BCY4
QRGAYQPGLVQPGAD	QRICH2	416	Q9H0J4
LTPGYHGFPARDSQG	RBFOX2	6	O43251
DYTPNRGHNGGGPDL	MTCL1	1436	Q9Y4B5
DVGPDGPFLRGYEQH	HLA-H	126	P01893
RQSTGSAPQGPAYHG	ARID1A	1511	O14497
HHLGYPVPGQLGNVV	FOXB2	296	Q5VYV0
PLGLDGYHIGRNQFP	GABBR1	646	Q9UBS5
NTRPRQPGGKDAHAY	KY	121	Q8NBH2
IYHLQPSGRFVIGGP	MAT2A	241	P31153
QRPVTPGGHRNGYPV	ARMC9	651	Q7Z3E5
PGGHRNGYPVVEDQH	ARMC9	656	Q7Z3E5
GELLHYPQVPGGARE	FREM2	231	Q5SZK8
LAHAYAPGPGINGDA	MMP3	181	P08254
VRGQARHPFGFGQVP	LOXL1	111	Q08397
VIIRGGGHILPYDQP	CPVL	441	Q9H3G5
PVGHVDIYPNGGTFQ	LPL	226	P06858
EGPSRLPGYASHQVG	NUDT6	131	P53370
PGLIGYPVHGFLQRD	FREM1	576	Q5H8C1
RRPHGDIYGINQALG	DGKA	616	P23743
VNHGYAEPAAGRELP	KCNA3	36	P22001
VGHIDIYPNGGDFQP	LIPG	236	Q9Y5X9
GQPIGGYTETQPHVA	MEIS3	341	Q99687
VYHLQPSGRFVIGGP	MAT1A	241	Q00266
GPANGRHYGIKPETR	HOXD9	151	P28356
PGSITHLNYRQGSIG	MED12	1826	Q93074
FTLGPVSPSHGGQYR	LILRA6	281	Q6PI73
GNAVLRGAHVYAPGI	NSUN6	121	Q8TEA1
GAQGTKYPEHGNPAI	EN1	236	Q05925
GSRGAPQHYPKTAGN	EIF4G2	21	P78344
GVRPPVGNRGHHQYN	TENT4A	736	Q5XG87
QPARYHVAFGPVIDG	NLGN3	366	Q9NZ94
EGLEPIGNVHPVGSY	CCSER2	516	Q9H7U1
AHLYQGLGPVVLSGP	GATA1	361	P15976
PGVQGAEHPNPGVRY	DTX3	246	Q8N9I9
GNGYDPQSHQITRGP	BOC	976	Q9BWV1
PEENHQGSNYGSPRP	CACNA1C	11	Q13936
AGIYGPGEQRHLPRI	SDR42E1	186	Q8WUS8
LNGRHTGTPFGDIPY	CR1	1781	P17927
PPKIQNGHYIGGHVS	CR1	1851	P17927
AGIQTEEHPNPGKRY	DTX3L	641	Q8TDB6
PSGDSLPYHQLQGGA	DSCR9	21	P59020
YHQLHGARQGTEPGG	FAM83C	686	Q9BQN1
HPGYDTGNGIQLPGT	FN1	2116	P02751
LNSGRVVPGYGHAVL	CS	336	O75390
PHVLQANGGAYGTPT	HOXB3	331	P14651
PYVLSQGGHPEDGNS	GJB4	236	Q9NTQ9
PQNGNSRHPSGYVPG	CEMIP2	16	Q9UHN6
YQENAPGLPVGAVAG	CEACAM3	141	P40198
VNYGSPPNLVEIHRG	BRWD1	141	Q9NSI6
GAGHAQRDPVGRYEP	LTBP2	31	Q14767
VLAGLYNPGDGHIDP	DMGDH	181	Q9UI17
PNGPHSIRNTPYDGV	MANEAL	286	Q5VSG8
APQVVLAPGGGAAYN	MAN2B1	866	O00754
PVYPRQRLGSSEHGQ	MBD5	196	Q9P267
YPTQGRRSPQEGGSH	FAM110B	166	Q8TC76
AEQRPGSILYGTHGP	FRY	1296	Q5TBA9
SAQSGYRVPGPQPGH	DCBLD1	616	Q8N8Z6
VGLLQGHPQCLDYGP	HHIPL2	36	Q6UWX4
SGSYGRVLLAQPHQG	SBK3	51	P0C264
TGRGPPLGFYHVQNI	KIF1A	1041	Q12756
VVLGLRATPAGGQHY	NOG	16	Q13253
LPHYAAGRQVPGGAF	MN1	256	Q10571
GGQLQPGYPALASRH	MMP11	321	P24347
GGTPYNNERHTPRAT	IGF2R	711	P11717
QHYQSGPVPGTAING	SOX2	296	P48431
GLPYQGHDSGVNLPD	SOX17	376	Q9H6I2
ESNHPGQTGGFVRVP	SH3D19	306	Q5HYK7
RQPIRGYVQPADTGH	SVIL	361	O95425
PGSHQGPDPYRQLRE	TMEM205	131	Q6UW68
LGHQDTREQPPGYAI	RHOT2	441	Q8IXI1
HEGRKYEPGESFQPG	KCP	1021	Q6ZWJ8
NGGRDYALRGPEHPG	PPP1R3E	251	Q9H7J1
AQVGQAYVGRPCLHP	PTCH2	241	Q9Y6C5
GSEQPGRPGSHGYVR	NCOR1	1741	O75376
RVGDVLPGPHTGDYA	SIPA1L3	21	O60292
AVELPDHNGLGYPAR	SIK3	1186	Q9Y2K2
QTLANVIRPCYGPHG	CCT8L1P	41	A6NM43
QQYSRPQGAVGGLEP	RHOXF2B	116	P0C7M4
GVLGLGPYPRQHEAD	OXCT1	346	P55809
PTHQGGPAQDRGVYL	SKIV2L	541	Q15477
EQPSPGHYGDQPRGS	SOX8	341	P57073
QRSGHLYTGREQPAP	STARD9	3286	Q9P2P6
LYTGREQPAPNHRGS	STARD9	3291	Q9P2P6
VYIFNGRHGGLSPQP	ITGAL	551	P20701
APGNPENGHSSGEIY	SVEP1	1791	Q4LDE5
QEGGAPIRYTPDGHL	OXCT2	166	Q9BYC2
LEIPPQYQAGGSGIH	RRP12	1206	Q5JTH9
RYVLHIQGSQGIGSP	SLC6A7	196	Q99884
AGPGNYVHPLTGRLL	SHANK2	1196	Q9UPX8
HLQGISGPILGQPFY	EIF4ENIF1	861	Q9NRA8
RGIGLGNYHPATENP	APC	856	P25054
SGNYTGIQIPPGAHA	VTA1	206	Q9NP79
YGLHEGQRVGPVSAV	TNXB	1441	P22105
NLYGFHGGQRVGPVS	TNXB	2261	P22105
NLYGFHGGQRVGPIS	TNXB	2911	P22105
YGLHEGQRVGPVSAV	TNXB	3021	P22105
EQPAHPLQVGAVYLG	TXNDC15	46	Q96J42
VGIYGRKGLPPSHTQ	TENM4	476	Q6N022
QQYSRPQGAVGGLEP	RHOXF2	116	Q9BQY4
GMTPLYAGQRLPQHG	ZMIZ2	236	Q8NF64
PDGKYIVTGENGHRP	WDR62	121	O43379
PPVVAGGNRSNTLHY	XPNPEP3	301	Q9NQH7
YEVHPRPGQDGAQAG	TNFSF12	111	O43508
DPDTYRLHVVGAPGG	SUOX	226	P51687
KSQGYRDGPGNPLRH	USP7	841	Q93009
RDGPGNPLRHNYEGT	USP7	846	Q93009
GNRLYVHPDSPNTGA	TBX21	216	Q9UL17
TSGVYHIAGPGPQQL	TNS2	336	Q63HR2
GHCYDITTGQPPRGL	UGGT1	1116	Q9NYU2
VAPPAATQNGHYGRG	ZBTB7A	261	O95365
LPGAGQYHRGLVTSP	ZBTB3	426	Q9H5J0